References
- Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2011. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2011/. based on November 2013 SEER data submission, posted to the SEER web site, April 2014
- Forman D, Bray F, Brewster DH, et al. Cancer incidence in five continents, Vol X. IARC Scientific Publication No. 164. Lyon: International Agency for Research on Cancer. http://ci5.iarc.fr/Default.aspx.
- Bassan R, Gatta G, Tondini C, Willemze R. Adult acute lymphoblastic leukemia. Crit Rev Oncol Hematol 2004;50:223–61
- Katz AJ, Chia VM, Schoonen WM, et al. Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden. Cancer Causes Control 2015;26:1627–42
- Food and Drug Administration (FDA). Blincyto drug approval package. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125557Orig1s000TOC.cfm. Last accessed February 2016
- Committee for Medicinal Products for Human Use (CHMP). Blinatumomab EPAR. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003731/WC500198227.pdf.
- Pui CH, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukemia. Nat Rev Drug Discov 2007;6:149–65
- Kantarjian HM, Thomas D, Ravandi F, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 2010;116:5568–74
- Gökbuget N. Recommendations of the European Working Group for Adult ALL, 1st edn. 2011
- Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011;29:532–43
- Tavernier E, Boiron JM, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007;21:1907–14
- Camera A, Annino L, Chiurazzi F, et al. GIMEMA ALL - Rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia. Haematologica 2004;89:145–53
- Di Bona E, Pogliani E, Rossi G, et al. Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients. Leuk Lymphoma 2005;46:879–84
- Giebel S, Krawczyk-Kulis M, Adamczyk-Cioch M, et al. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG). Ann Hematol 2006;85:717–22
- Advani AS, Gundacker HM, Sala-Torra O, et al. Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukemia. Br J Haematol 2010;151:430–34
- O’Brien S, Thomas D, Ravandi F. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 2008;113:3186–91
- Saito AM, Cutler C, Zahrieh D, et al. Cost of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant 2008;14:197–207
- Khera N, Zeliadt SB, Lee SJ. Economics of hematopoietic cell transplantation. Blood 2012;23:1545–51
- Barlev A, Lin VW, Song X. Burden of hospitalization in relapsed acute lymphoblastic leukemia. Curr Med Res Opin 2016:1–16. [Epub ahead of print]
- Pagano L, Oberti M, Esposito B, et al. Retrospective chart review of hospitalizations during chemotherapy for adult patients with Ph-negative B-precursor relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) in Italy. Value Health 2015;18:A443
- Kreuzer K, Stuhlmann R, Lebioda A, et al. Hospitalizations among adult patients with Ph-negative B-precursor relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) receiving chemotherapy in Germany: a retrospective chart review. Value Health 2015;18:A443
- Fielding AK, Richards SM, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007;109:944–50
- Oriol A, Vives S, Hernandez-Rivas JM, Chopra R. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 2010;95:589–96